DOCSLIB.ORG

SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1 The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis, unspecified 3 A5481 Gonococcal meningitis 3 A5482 Gonococcal brain abscess 3 A6921 Meningitis due to Lyme disease 3 B375 Candidal meningitis 3 B384 Coccidioidomycosis meningitis 3 B4081 Blastomycotic meningoencephalitis 3 B4281 Cerebral sporotrichosis 3 B431 Pheomycotic brain abscess 3 B5741 Meningitis in Chagas' disease 3 B5742 Meningoencephalitis in Chagas' disease 3 B6011 Meningoencephalitis due to Acanthamoeba (culbertsoni) 3 G000 Hemophilus meningitis 3 G001 Pneumococcal meningitis 3 G002 Streptococcal meningitis 3 G003 Staphylococcal meningitis 3 G008 Other bacterial meningitis 3 G009 Bacterial meningitis, unspecified 3 G01 Meningitis in bacterial diseases classified elsewhere 3 G02 Meningitis in other infectious and parasitic diseases classified elsewhere 3 G0400 Acute disseminated encephalitis and encephalomyelitis, unspecified 3 G0401 Postinfectious acute disseminated encephalitis and encephalomyelitis (postinfectious ADEM) 3 G0402 Postimmunization acute disseminated encephalitis, myelitis and encephalomyelitis 3 G042 Bacterial meningoencephalitis and meningomyelitis, not elsewhere classified 3 G0430 Acute necrotizing hemorrhagic encephalopathy, unspecified 3 G0431 Postinfectious acute necrotizing hemorrhagic encephalopathy 3 G0432 Postimmunization acute necrotizing hemorrhagic encephalopathy 3 G0439 Other acute necrotizing hemorrhagic encephalopathy 3 G0481 Other encephalitis and encephalomyelitis 3 G0490 Encephalitis and encephalomyelitis, unspecified 3 G053 Encephalitis and encephalomyelitis in diseases classified elsewhere 3 G060 Intracranial abscess and granuloma 3 G061 Intraspinal abscess and granuloma 3 G062 Extradural and subdural abscess, unspecified 3 G07 Intracranial and intraspinal abscess and granuloma in diseases classified elsewhere 3 G08 Intracranial and intraspinal phlebitis and thrombophlebitis 4 A800 Acute paralytic poliomyelitis, vaccine-associated 4 A801 Acute paralytic poliomyelitis, wild virus, imported 4 A802 Acute paralytic poliomyelitis, wild virus, indigenous 4 A8030 Acute paralytic poliomyelitis, unspecified 4 A8039 Other acute paralytic poliomyelitis 4 A804 Acute nonparalytic poliomyelitis 4 A809 Acute poliomyelitis, unspecified 4 A820 Sylvatic rabies 4 A821 Urban rabies 4 A829 Rabies, unspecified 4 A830 Japanese encephalitis 4 A831 Western equine encephalitis 4 A832 Eastern equine encephalitis 4 A833 St Louis encephalitis 4 A834 Australian encephalitis 4 A835 California encephalitis 4 A836 Rocio virus disease 4 A838 Other mosquito-borne viral encephalitis 4 A839 Mosquito-borne viral encephalitis, unspecified 4 A840 Far Eastern tick-borne encephalitis [Russian spring-summer encephalitis] 4 A841 Central European tick-borne encephalitis 4 A848 Other tick-borne viral encephalitis 4 A849 Tick-borne viral encephalitis, unspecified 4 A850 Enteroviral encephalitis 4 A851 Adenoviral encephalitis 4 A852 Arthropod-borne viral encephalitis, unspecified 4 A858 Other specified viral encephalitis 4 A86 Unspecified viral encephalitis 4 A870 Enteroviral meningitis 4 A871 Adenoviral meningitis 4 A872 Lymphocytic choriomeningitis 4 A878 Other viral meningitis 4 A879 Viral meningitis, unspecified 4 A880 Enteroviral exanthematous fever [Boston exanthem] 4 A888 Other specified viral infections of central nervous system 4 A89 Unspecified viral infection of central nervous system 4 A922 Venezuelan equine fever 4 A9230 West Nile virus infection, unspecified 4 A9231 West Nile virus infection with encephalitis 4 A9232 West Nile virus infection with other neurologic manifestation 4 A9239 West Nile virus infection with other complications 4 B003 Herpesviral meningitis 4 B004 Herpesviral encephalitis 4 B010 Varicella meningitis 4 B0111 Varicella encephalitis and encephalomyelitis 4 B020 Zoster encephalitis 4 B021 Zoster meningitis 4 B050 Measles complicated by encephalitis 4 B051 Measles complicated by meningitis 4 B0601 Rubella encephalitis 4 B0602 Rubella meningitis 4 B1001 Human herpesvirus 6 encephalitis 4 B1009 Other human herpesvirus encephalitis 4 B261 Mumps meningitis 4 B262 Mumps encephalitis 4 B2702 Gammaherpesviral mononucleosis with meningitis 4 B2712 Cytomegaloviral mononucleosis with meningitis 4 B2782 Other infectious mononucleosis with meningitis 4 B2792 Infectious mononucleosis, unspecified with meningitis 4 B900 Sequelae of central nervous system tuberculosis 4 B91 Sequelae of poliomyelitis 4 B941 Sequelae of viral encephalitis 4 D8681 Sarcoid meningitis 4 G030 Nonpyogenic meningitis 4 G031 Chronic meningitis 4 G032 Benign recurrent meningitis [Mollaret] 4 G038 Meningitis due to other specified causes 4 G039 Meningitis, unspecified 4 G09 Sequelae of inflammatory diseases of central nervous system 4 G14 Postpolio syndrome 7 A000 Cholera due to Vibrio cholerae 01, biovar cholerae 7 A001 Cholera due to Vibrio cholerae 01, biovar eltor 7 A009 Cholera, unspecified 7 A0100 Typhoid fever, unspecified 7 A0109 Typhoid fever with other complications 7 A011 Paratyphoid fever A 7 A012 Paratyphoid fever B 7 A013 Paratyphoid fever C 7 A014 Paratyphoid fever, unspecified 7 A050 Foodborne staphylococcal intoxication 7 A051 Botulism food poisoning 7 A052 Foodborne Clostridium perfringens [Clostridium welchii] intoxication 7 A053 Foodborne Vibrio parahaemolyticus intoxication 7 A054 Foodborne Bacillus cereus intoxication 7 A055 Foodborne Vibrio vulnificus intoxication 7 A058 Other specified bacterial foodborne intoxications 7 A059 Bacterial foodborne intoxication, unspecified 7 A060 Acute amebic dysentery 7 A061 Chronic intestinal amebiasis 7 A062 Amebic nondysenteric colitis 7 A063 Ameboma of intestine 7 A0681 Amebic cystitis 7 A0682 Other amebic genitourinary infections 7 A0689 Other amebic infections 7 A069 Amebiasis, unspecified 7 A070 Balantidiasis 7 A071 Giardiasis [lambliasis] 7 A073 Isosporiasis 7 A074 Cyclosporiasis 7 A078 Other specified protozoal intestinal diseases 7 A079 Protozoal intestinal disease, unspecified 7 A080 Rotaviral enteritis 7 A0811 Acute gastroenteropathy due to Norwalk agent 7 A0819 Acute gastroenteropathy due to other small round viruses 7 A082 Adenoviral enteritis 7 A0831 Calicivirus enteritis 7 A0832 Astrovirus enteritis 7 A0839 Other viral enteritis 7 A084 Viral intestinal infection, unspecified 7 A088 Other specified intestinal infections 7 A09 Infectious gastroenteritis and colitis, unspecified 7 A200 Bubonic plague 7 A208 Other forms of plague 7 A209 Plague, unspecified 7 A210 Ulceroglandular tularemia 7 A211 Oculoglandular tularemia 7 A213 Gastrointestinal tularemia 7 A217 Generalized tularemia 7 A218 Other forms of tularemia 7 A219 Tularemia, unspecified 7 A222 Gastrointestinal anthrax 7 A228 Other forms of anthrax 7 A229 Anthrax, unspecified 7 A230 Brucellosis due to Brucella melitensis 7 A231 Brucellosis due to Brucella abortus 7 A232 Brucellosis due to Brucella suis 7 A233 Brucellosis due to Brucella canis 7 A238 Other brucellosis 7 A239 Brucellosis, unspecified 7 A240 Glanders 7 A241 Acute and fulminating melioidosis 7 A242 Subacute and chronic melioidosis 7 A243 Other melioidosis 7 A249 Melioidosis, unspecified 7 A250 Spirillosis 7 A251 Streptobacillosis 7 A259 Rat-bite fever, unspecified 7 A260 Cutaneous erysipeloid 7 A268 Other forms of erysipeloid 7 A269 Erysipeloid, unspecified 7 A270 Leptospirosis icterohemorrhagica 7 A2789 Other forms of leptospirosis 7 A279 Leptospirosis, unspecified 7 A280 Pasteurellosis 7 A281 Cat-scratch disease 7 A282 Extraintestinal yersiniosis 7 A288 Other specified zoonotic bacterial diseases, not elsewhere classified 7 A289 Zoonotic bacterial disease, unspecified 7 A300 Indeterminate leprosy 7 A301 Tuberculoid leprosy 7 A302 Borderline tuberculoid leprosy 7 A303 Borderline leprosy 7 A304 Borderline lepromatous leprosy 7 A305 Lepromatous leprosy 7 A308 Other forms of leprosy 7 A309 Leprosy, unspecified 7 A318 Other mycobacterial infections 7 A319 Mycobacterial infection, unspecified 7 A320 Cutaneous listeriosis 7 A3281 Oculoglandular listeriosis 7 A3289 Other forms of listeriosis 7 A329 Listeriosis,
Load more

Recommended publications
  • Introduction to the Arthropods
    Ticks General Tick Biology Life cycle has 4 stages: egg, 6-legged larvae, 8-legged nymph, & adult Must consume blood from a host at every stage to develop – each stage must find a new host Pierces skin and attaches to host with mouthparts Feed on mammals, birds, & lizards Larvae & nymphs prefer smaller hosts Life cycle Hard ticks vs Soft ticks Harm to humans Direct injures 1. Irritation: sting, secondary infection, allergy 2. Tick paralysis: paralysis of the motor nerves --- cannot walk or stand, has difficulty in speaking, swallowing and breathing. Transmission of diseases Three medically important tick species American dog tick Blacklegged tick or deer tick Lone star tick. American Dog Tick: Diseases - Carries Rocky Mountain spotted fever - Can also transmit tularemia - Injected dog tick saliva can cause tick paralysis (tick neurotoxin) - Infected tick attached to host 4 – 6 hours before transmitting disease Blacklegged tick or deer tick - Smaller than other ticks - males 1/16”, females ~3/32” - Both sexes are dark chocolate brown, but rear half of adult female is red or orange - Larval stage is nearly translucent - Engorged adult females are brownish Carries Lyme disease May also carry anaplasmosis & ehrlichiosis Can infect a host with two or more diseases simultaneously Infected tick attached to host 36 – 48 hours before disease transmission Lone star tick Adult female is ~3/16” long, brown with distinct silvery spot on upper scutum Male is ~3/16” long, brown with whitish markings along rear edge. Engorged female is almost
    [Show full text]
  • Balantidium Coli
    GLOBAL WATER PATHOGEN PROJECT PART THREE. SPECIFIC EXCRETED PATHOGENS: ENVIRONMENTAL AND EPIDEMIOLOGY ASPECTS BALANTIDIUM COLI Francisco Ponce-Gordo Complutense University Madrid, Spain Kateřina Jirků-Pomajbíková Institute of Parasitology Biology Centre, ASCR, v.v.i. Budweis, Czech Republic Copyright: This publication is available in Open Access under the Attribution-ShareAlike 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/by-sa/3.0/igo). By using the content of this publication, the users accept to be bound by the terms of use of the UNESCO Open Access Repository (http://www.unesco.org/openaccess/terms-use-ccbysa-en). Disclaimer: The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they are not necessarily those of UNESCO and do not commit the Organization. Citation: Ponce-Gordo, F., Jirků-Pomajbíková, K. 2017. Balantidium coli. In: J.B. Rose and B. Jiménez-Cisneros, (eds) Global Water Pathogens Project. http://www.waterpathogens.org (R. Fayer and W. Jakubowski, (eds) Part 3 Protists) http://www.waterpathogens.org/book/balantidium-coli Michigan State University, E. Lansing, MI, UNESCO. Acknowledgements: K.R.L. Young, Project Design editor; Website Design (http://www.agroknow.com) Published: January 15, 2015, 11:50 am, Updated: October 18, 2017, 5:43 pm Balantidium coli Summary 1.1.1 Global distribution Balantidium coli is reported worldwide although it is To date, Balantidium coli is the only ciliate protozoan more common in temperate and tropical regions (Areán and reported to infect the gastrointestinal track of humans.
    [Show full text]
  • ICD10 Diagnoses FY2018 AHD.Com
    ICD10 Diagnoses FY2018 AHD.com A020 Salmonella enteritis A5217 General paresis B372 Candidiasis of skin and nail A040 Enteropathogenic Escherichia coli A523 Neurosyphilis, unspecified B373 Candidiasis of vulva and vagina infection A528 Late syphilis, latent B3741 Candidal cystitis and urethritis A044 Other intestinal Escherichia coli A530 Latent syphilis, unspecified as early or B3749 Other urogenital candidiasis infections late B376 Candidal endocarditis A045 Campylobacter enteritis A539 Syphilis, unspecified B377 Candidal sepsis A046 Enteritis due to Yersinia enterocolitica A599 Trichomoniasis, unspecified B3781 Candidal esophagitis A047 Enterocolitis due to Clostridium difficile A6000 Herpesviral infection of urogenital B3789 Other sites of candidiasis A048 Other specified bacterial intestinal system, unspecified B379 Candidiasis, unspecified infections A6002 Herpesviral infection of other male B380 Acute pulmonary coccidioidomycosis A049 Bacterial intestinal infection, genital organs B381 Chronic pulmonary coccidioidomycosis unspecified A630 Anogenital (venereal) warts B382 Pulmonary coccidioidomycosis, A059 Bacterial foodborne intoxication, A6920 Lyme disease, unspecified unspecified unspecified A7740 Ehrlichiosis, unspecified B387 Disseminated coccidioidomycosis A080 Rotaviral enteritis A7749 Other ehrlichiosis B389 Coccidioidomycosis, unspecified A0811 Acute gastroenteropathy due to A879 Viral meningitis, unspecified B399 Histoplasmosis, unspecified Norwalk agent A938 Other specified arthropod-borne viral B440 Invasive pulmonary
    [Show full text]
  • Quantitative Analysis of Bcl-2 Expression in Normal and Leukemic Human B-Cell Differentiation
    Leukemia (2004) 18, 491–498 & 2004 Nature Publishing Group All rights reserved 0887-6924/04 $25.00 www.nature.com/leu Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation P Menendez1,2, A Vargas3, C Bueno1,2, S Barrena1,2, J Almeida1,2 M de Santiago1,2,ALo´pez1,2, S Roa2, JF San Miguel2,4 and A Orfao1,2 1Servicio General de Citometrı´a, Universidad de Salamanca, Salamanca, Spain; 2Departamento de Medicina and Centro de Investigacio´n del Ca´ncer, Universidad de Salamanca, Salamanca, Spain; 3Servicio de Inmunodiagno´stico, Departamento de Patologı´a Clı´nica, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru´, ; and 4Servicio de Hematologı´a, Hospital Universitario, Salamanca, Spain Lack of apoptosis has been linked to prolonged survival of results in the overexpression of the bcl-2 protein and it malignant B cells expressing bcl-2. The aim of the present represented the first clear example of a common step in study was to analyze the amount of bcl-2 protein expressed 9,10 along normal human B-cell maturation and to establish the oncogenesis mediated by decreased cell death. Currently, frequency of aberrant bcl-2 expression in B-cell malignancies. the exact antiapoptotic pathways through which bcl-2 exerts its In normal bone marrow (n ¼ 11), bcl-2 expression obtained by role are only partially understood, involving decreased mito- quantitative multiparametric flow cytometry was highly vari- chondrial release of cytochrome c, which in turn is required for þ À able: very low in both CD34 and CD34 B-cell precursors, high the activation of procaspase-9 and the subsequent initiation of in mature B-lymphocytes and very high in plasma cells.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Cardisure 3.5 mg/ml Oral Solution for Dogs 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ​Each ml contains ​ ​ ​Active substance: ​ ​ ​Pimobendan 3.5​ ​mg ​Excipients: ​ ​ ​Benzyl alcohol (E1519) 1.0​ mg​ ​For the full list of excipients, see section 6.1. ​ ​ 3 PHARMACEUTICAL FORM Oral Solution. Clear, colourless, semi-viscous liquid. 4 CLINICAL PARTICULARS 4.1 Target Species Dogs. 4.2 Indications for use, specifying the target species For the treatment of canine congestive heart failure originating from valvular insufficiency (mitral and/or tricuspid regurgitation) or dilated cardiomyopathy. 4.3 Contraindications Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). Do not use in dogs with severe impairment of liver function, as pimobendan is metabolised mainly via the liver. Do not use in cases of known hypersensitivity to the active substance or to any of the excipients. 4.4 Special warnings for each target species None known. 4.5 Special precautions for use Special precautions for use in animals The blood glucose should be tested regularly during treatment in dogs with existing diabetes mellitus. Monitoring of cardiac function and morphology is recommended in animals treated with pimobendan (See also section 4.6). Special precautions to be taken by the person administering the veterinary medicinal product to animals Accidental ingestion, especially by a child, may lead to the occurrence of tachycardia, orthostatic hypotension, flushing of the face and headaches.
    [Show full text]
  • Educational Achievement and Economic Self-Sufficiency in Adults After Childhood Bacterial Meningitis
    1 Supplementary Online Content Roed C, Omland LH, Skinhoj P, Rothman KJ, Sorensen HT, Obel N. Educational achievement and economic self-sufficiency in adults after childhood bacterial meningitis. JAMA. doi:10.1001/jama.2013.3792 Appendix 1. Description of Registries Appendix 2. Diagnosis Codes for Intrauterine and Birth Asphyxia or Chromosomal Abnormalities Appendix 3. Diagnosis Codes for Meningococcal, Pneumococcal, Or H influenzae Meningitis Appendix 4. Diagnosis Codes for Neuroinfections Other Than Bacterial Meningitis eTable 1. Number of Events in the Study Population and Total Observation Time eTable 2. Estimated Prevalence at Age 35 of Vocational Education, High School, Higher Education, Economic Self‐sufficiency and Disability pension Among Meningitis Patients, Members of the Population Comparison Cohorts, and Their Siblings Without Neonatal Morbidity eFigure 1. Cumulative Incidence of Having Been Economically Self‐sufficient for a Year and of Receiving Disability Pension in the Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Siblings of Members of the Population Comparison Cohort (Blue) eFigure 2. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born Before 1980 eFigure 3. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born After 1980 This supplementary material has been provided by the authors to give readers additional information about their work.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • The Intestinal Protozoa
    The Intestinal Protozoa A. Introduction 1. The Phylum Protozoa is classified into four major subdivisions according to the methods of locomotion and reproduction. a. The amoebae (Superclass Sarcodina, Class Rhizopodea move by means of pseudopodia and reproduce exclusively by asexual binary division. b. The flagellates (Superclass Mastigophora, Class Zoomasitgophorea) typically move by long, whiplike flagella and reproduce by binary fission. c. The ciliates (Subphylum Ciliophora, Class Ciliata) are propelled by rows of cilia that beat with a synchronized wavelike motion. d. The sporozoans (Subphylum Sporozoa) lack specialized organelles of motility but have a unique type of life cycle, alternating between sexual and asexual reproductive cycles (alternation of generations). e. Number of species - there are about 45,000 protozoan species; around 8000 are parasitic, and around 25 species are important to humans. 2. Diagnosis - must learn to differentiate between the harmless and the medically important. This is most often based upon the morphology of respective organisms. 3. Transmission - mostly person-to-person, via fecal-oral route; fecally contaminated food or water important (organisms remain viable for around 30 days in cool moist environment with few bacteria; other means of transmission include sexual, insects, animals (zoonoses). B. Structures 1. trophozoite - the motile vegetative stage; multiplies via binary fission; colonizes host. 2. cyst - the inactive, non-motile, infective stage; survives the environment due to the presence of a cyst wall. 3. nuclear structure - important in the identification of organisms and species differentiation. 4. diagnostic features a. size - helpful in identifying organisms; must have calibrated objectives on the microscope in order to measure accurately.
    [Show full text]
  • Neuropsychological Testing
    Medical Coverage Policy Effective Date ............................................. 8/15/2021 Next Review Date ....................................... 8/15/2022 Coverage Policy Number .................................. 0258 Neuropsychological Testing Table of Contents Related Coverage Resources Overview .............................................................. 1 Attention-Deficit/Hyperactivity Disorder: Assessment Coverage Policy ................................................... 1 and Treatment General Background ............................................ 2 Autism Spectrum Disorder/Pervasive Developmental Medicare Coverage Determinations .................. 15 Disorders: Assessment and Treatment Coding/Billing Information .................................. 16 Cognitive Rehabilitation Lyme Disease Treatment— Antibiotic Treatment References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
    [Show full text]
  • Dynamic Analysis of Cardiovascular Drugs Data
    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(5):1517-1520 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Dynamic analysis of cardiovascular drugs data Humei Yang and SunShi The Affiliated Hospital of Qingdao University Medical College , China _____________________________________________________________________________________________ ABSTRACT Cardiovascular disease is an important disease which is a serious hazard to human health, not only that, but the cause is still quite complicated. Therefore, it is very important to carry out research work of cardiovascular drugs in the medical profession. In this article, the money amount sequence method and DDD number sequence method were used to statistically analyze the data of cardiovascular drugs which were purchased by patients in a hospital in Shanghai in 2010-2013 year. The data of cardiovascular drugs second-class hospitals and upper-class hospitals in Shanghai included the drug varieties, prescription medication, the amount of money, which were statistically analyzed in order to provide recommendations for future cardiovascular medication guide. Through this research, we have come to the result that the money of cardiovascular drugs accounts greater of the amount of all of the drugs in the second-class hospitals than that in the upper-class hospitals, and cardiovascular medication amounts, prescriptions, etc of the second-class hospitals and upper-class hospitals had increased than before. Calcium antagonists and angiotensin ⅱ receptor antagonist drugs led occupation, as well as a small amount of varieties of drugs had gone into the top 10 amounts .As for cardiovascular drugs, foreign markets occupy a major market. That is to say that between different levels of hospitals there is some difference in cardiovascular drug use, but the drugs with good effects are already the first choice.
    [Show full text]
  • Academy of Medical Sciences of Ukraine L. V. Gromashevskiy
    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy Institute of Epidemiology and Infektious Diseases Panasiuk Olena Leonidivna ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 14.01.13 — Infektious Diseases Kyiv — 2007 TABLE OF CONTENTS LIST OF ABBREVIATIONS USED INTRODUCTION CHAPTER 1 PRESSING ISSUES OF TREATMENT OF HERPES VIRUS INFECTIONS 1.2. Main principles of treatment of patients with herpes virus infections CHAPTER 2 MATERIALS AND STUDY METHODS 2.1. Characteristic of examined patients 2.2. Characteristic of study drug and treatment methods 2.3. Study design 2.3.1. Subjects enrollment and discontinuation criteria 2.3.2. Principles and algorithm of subjects grouping 2.3.3. Assessment of therapy efficacy 2.4. Study methods 2.4.1. Clinical method 2.4.2. Special study methods 2.4.3. Statistical method CHAPTER 3 ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 3.1. Clinical efficacy of Proteflazid 3.2. Adverse effects of therapy with Proteflazid 3.3. Interferon inducing and immunomodulatory activity of Proteflazid in subjects with herpes virus infection 3.3.1. Immunomodulatory activity of Proteflazid 3.3.2. Interferon inducing properties of Proteflazid CHAPTER 4 LONG-TERM RESULTS OF TREATMENT OF HERPES VIRUS INFECTION 4.1. Anti-relapse efficacy of Proteflazid CONCLUSIONS PRACTICAL GUIDELINES REFERENCES List of abbreviations used NK (CD16) — natural killer cells NSE — neurospecific enolase ME — meningoencerebritis ANAD — acyclic nucleoside antiviral drugs AB — antibody
    [Show full text]
  • Primary Amoebic Meningoencephalitis Amoebic Meningoencephalitis Is Primary Ś
    PØEHLEDOVÉ PRÁCE PØEHLEDOVÉ JE NEGLERIÓZA VEREJNO-ZDRAVOTNÍCKYM PROBLÉMOM? IS PRIMARY AMOEBIC MENINGOENCEPHALITIS (NAEGLERIASIS) A PUBLIC HEALTH PROBLEM? KATARÍNA TRNKOVÁ, LUCIA MAĎAROVÁ, CYRIL KLEMENT Regionálny úrad verejného zdravotníctva so sídlom v Banskej Bystrici, odbor lekárskej mikrobiológie SOUHRN Neglerióza alebo primárna amébová meningoencefalitída (PAM) je zriedkavé ochorenie CNS, pôvodcom ktorého je vo¾ne žijúca meòavka Naegleria fowleri. Medzi stovkami vo¾ne žijúcich meòaviek sú známe i ïalšie rody, ktorých zástupcovia sú schopní infikovaś èloveka a vyvolaś u neho ochorenie. Za patogény sú považovaní zástupcovia rodov Acanthamoeba a Naegleria a druhy Balamuthia mandrillaris a Sappi- nia diploidea. Infekcie spôsobené týmito organizmami vyvolávajú u ¾udí syndrómy v rozsahu od akútnych fatálnych ochorení po chronické, tkanivá napadajúce infekcie s granulomatóznymi prejavmi. Epidemiológia, imunológia, patológia a klinické prejavy týchto infekcií sa vzájomne ve¾mi líšia. Príspevok podáva preh¾ad o pôvodcovi ochorenia PAM, o jeho morfológii, životnom cykle, ekológii ako aj o patogenéze, symptomatike a spôsoboch laboratórnej diagnostiky negleriózy. K¾úèové slová: neglerióza, primárna amébová meningoencefalitída, epidemiológia, laboratórna diagnostika Naegleria fowleri SUMMARY Naegleriasis or primary amoebic meningoencephalitis (PAM) is invariably an acute, often fulminant infection of CNS caused by Naegleria fowleri, a small, free-living amoeba. Pathogenic free-living amoebae can cause serious illnesses in humans. The amoe- HYGIENA bae belonging to the genus Naegleria, Acanthamoeba and Balamuthia mandrillaris and Sappinia diploidea produce syndromes in man ranging from acute fatal disease to chronic tissue invasion with granulomatous manifestation. The purpose of this report is to describe the clinical history, treatment, pathology and methods of laboratory diagnostic of naegleriasis. Key words: primary amoebic meningoencephalitis, naegleriasis, epidemiology, laboratory diagnostics of Naegleria fowleri ÈÍSLO 2 Úvod Obr.
    [Show full text]